ImmuCell (ICCC) Getting Somewhat Favorable Media Coverage, Report Shows

News headlines about ImmuCell (NASDAQ:ICCC) have been trending somewhat positive recently, according to Accern. Accern scores the sentiment of news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. ImmuCell earned a news impact score of 0.16 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 45.9692422144222 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Separately, ValuEngine raised shares of ImmuCell from a “sell” rating to a “hold” rating in a report on Wednesday, October 18th.

Shares of ImmuCell (ICCC) traded down $0.21 during mid-day trading on Tuesday, reaching $7.17. 3,000 shares of the company’s stock were exchanged, compared to its average volume of 8,885. ImmuCell has a twelve month low of $5.00 and a twelve month high of $9.25. The stock has a market capitalization of $40.41, a PE ratio of -179.25 and a beta of 1.03. The company has a current ratio of 1.75, a quick ratio of 0.99 and a debt-to-equity ratio of 0.27.

ImmuCell (NASDAQ:ICCC) last announced its earnings results on Thursday, February 8th. The biotechnology company reported ($0.04) EPS for the quarter. ImmuCell had a negative net margin of 1.61% and a negative return on equity of 0.82%. The business had revenue of $3.13 million for the quarter.

WARNING: This piece of content was reported by Transcript Daily and is owned by of Transcript Daily. If you are viewing this piece of content on another site, it was illegally copied and reposted in violation of US and international copyright & trademark law. The legal version of this piece of content can be read at

About ImmuCell

ImmuCell Corporation is an animal health company. The Company operates in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries segment. The Company has developed products that provide immediate immunity to newborn dairy and beef cattle, and is developing product line extensions of its existing products that address mastitis.

Insider Buying and Selling by Quarter for ImmuCell (NASDAQ:ICCC)

Receive News & Ratings for ImmuCell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuCell and related companies with's FREE daily email newsletter.

Leave a Reply